文献速递流行病学与生物统计临床试验与 GCP

COVID-19大流行与新临床试验启动

The COVID-19 pandemic and new clinical trial activations.
PubMed 文献 · Trials · 2021-04-08

该回顾性队列研究基于ClinicalTrials.gov数据,采用中断时间序列分析,评估COVID-19疫情与肿瘤、心血管和心理健康领域新临床试验启动的关联。研究发现,2020年2月至5月美国研究月度启动数仅为预期57%,非美国研究为77%,美国受影响更严重;重启阶段反弹也较弱。

要点

  • COVID-19初期美国新临床试验启动降至预期57%,非美国为77%。
  • 美国试验启动相对风险比非美国低27%,反弹阶段也较弱。
  • 癌症临床试验启动减少可能延缓临床研究与新药发现。

核心结论

  • COVID-19大流行初期新临床试验启动显著减少,美国受影响程度大于非美国。

研究设计与样本

  • 回顾性队列研究,分析2015年1月至2020年9月ClinicalTrials.gov上肿瘤、心血管和心理健康领域的干预性与观察性研究。
  • 采用中断时间序列分析与泊松回归。
  • 共检查62,252例试验启动。

主要发现

  • 2020年2月至5月,美国研究月度试验启动数为未发生疫情时预期估计的57%(相对风险=0.57,95%CI 0.52-0.61,p<.001)。
  • 非美国研究相对风险=0.77(95%CI 0.73-0.82,p<.001)。
  • 美国试验相对非美国试验的新启动相对风险降低27%(相对风险比=0.73,95%CI 0.67-0.81,p<.001)。
  • 2020年6月至9月重启阶段出现反弹,但美国研究反弹弱于非美国研究(相对风险比=0.87,95%CI 0.80-0.95,p<.001)。

临床怎么用

  • 提示疫情等突发公共卫生事件期间需关注临床试验启动的持续性与区域差异。
  • 癌症临床试验启动减少可能影响患者参与新药研究的机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COVID-19 pandemic has caused severe disruptions in care for many patients. A key question is whether the landscape of clinical research has also changed. METHODS: In a retrospective cohort study, we examined the association of the COVID-19 outbreak with new clinical trial activations. Trial data for all interventional and observational oncology, cardiovascular, and mental health studies from January 2015 through September 2020 were obtained from ClinicalTrials.gov . An interrupted time-series analysis with Poisson regression was used. RESULTS: We examined 62,252 trial activations. During the initial COVID-19 outbreak (February 2020 through May 2020), model-estimated monthly trial activations for US-based studies were only 57% of the expected estimate had the pandemic not occurred (relative risk = 0.57, 95% CI 0.52 to 0.61, p < .001). For non-US-based studies, the impact of the pandemic was less dramatic (relative risk = 0.77, 95% CI 0.73 to 0.82, p < .001), resulting in an overall 27% reduction in the relative risk of new trial activations for US-based trials compared to non-US-based trials (relative risk ratio = 0.73, 95% CI 0.67 to 0.81, p < .001). Although a rebound occurred in the initial reopening phase (June 2020 through September 2020), the rebound was weaker for US-based studies compared to non-US-based studies (relative risk ratio = 0.87, 95% CI 0.80 to 0.95, p < .001). CONCLUSIONS: These findings are consistent with the disproportionate burden of COVID-19 diagnoses and deaths during the initial phase of the pandemic in the USA. Reduced activation of cancer clinical trials will likely slow the pace of clinical research and new drug discovery, with long-term negative consequences for cancer patients. An important question is whether the renewed outbreak period of winter 2020/2021 will have a similarly negative impact on the initiation of new clinical research studies for non-COVID-19 diseases.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Unger JM, Xiao H. The COVID-19 pandemic and new clinical trial activations. Trials. 2021. PMID: 33832534. doi:10.1186/s13063-021-05219-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。